Literature DB >> 18385171

Pre-immigration screening process and pulmonary tuberculosis among Ethiopian migrants in Israel.

Z Mor1, Y Lerman, A Leventhal.   

Abstract

More than 75,000 displaced Ethiopians have moved to Israel. Tuberculosis (TB) incidence in Ethiopia is 44 times higher than in Israel (344 versus 8 cases per 100,000 inhabitants, respectively). The aims of the present retrospective cohort study were to evaluate the pre-immigration screening process initiated in 2001 on pulmonary TB (PTB) morbidity and to assess its cost-effectiveness. Ethiopian immigrants who were screened before departure (study group) were compared with those who were screened after arrival (comparison group). Between 1998 and 2005, 24,051 Ethiopian immigrants arrived in Israel. PTB was diagnosed in 332 (1.4%) immigrants, an incidence density of 325 patients per 100,000 person-yrs. PTB cumulative incidence was lower in the study group than in the comparison group: 711 compared with 1,746 patients per 100,000 immigrants, respectively (rate ratio 0.4). PTB was detected significantly earlier in the study group than in the comparison group: 193 versus 487 days after entry, respectively. Disease incidence declined significantly during the first 2 yrs following immigration. A 5-yr predictive model indicated that 98 individuals would be free of PTB, saving US$91,055 on annual treatment cost, due to screening. The pre-immigration screening process reduced pulmonary tuberculosis incidence in subsequent years following immigration. Pulmonary tuberculosis was diagnosed earlier in the screened group than in the comparison group and the process was found to be both cost-beneficial and cost-effective.

Entities:  

Mesh:

Year:  2008        PMID: 18385171     DOI: 10.1183/09031936.00145907

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  8 in total

Review 1.  Infectious diseases among Ethiopian immigrants in Israel: a descriptive literature review.

Authors:  Yulia Treister-Goltzman; Ali Alhoashle; Roni Peleg
Journal:  Pathog Glob Health       Date:  2021-02-24       Impact factor: 2.894

2.  HIV prevalence in the Israeli tuberculosis cohort, 1999-2011.

Authors:  Mor Zohar; Lidji Moshe; Chemtob Daniel; Cedar Noa; Grotto Itamar
Journal:  BMC Public Health       Date:  2014-10-21       Impact factor: 3.295

3.  Effectiveness of service models and organisational structures supporting tuberculosis identification and management in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review.

Authors:  Charlotte C Heuvelings; Patrick F Greve; Sophia G de Vries; Benjamin Visser; Sabine Bélard; Saskia Janssen; Anne L Cremers; René Spijker; Elizabeth Shaw; Ruaraidh A Hill; Alimuddin Zumla; Andreas Sandgren; Marieke J van der Werf; Martin Peter Grobusch
Journal:  BMJ Open       Date:  2018-09-08       Impact factor: 2.692

4.  Challenges of tuberculosis management in high and low prevalence countries in a mobile world.

Authors:  Chris Griffiths; Monica Barne; Puneet Saxena; John Yaphe
Journal:  Prim Care Respir J       Date:  2014-03

5.  Smear Posetive Pulmonary Tuberculosis (PTB) Prevalence Amongst Patients at Agaro Teaching Health Center, South West Ethiopia.

Authors:  Hussen Ali; Ahmed Zeynudin; Abiyu Mekonnen; Solomon Abera; Solomon Ali
Journal:  Ethiop J Health Sci       Date:  2012-03

6.  Tuberculosis incidence in HIV/AIDS patients in Israel, 1983-2010.

Authors:  Zohar Mor; Moshe Lidji; Noa Cedar; Itamar Grotto; Daniel Chemtob
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

7.  Tuberculosis outbreak in a nursing home involving undocumented migrants and Israeli citizens.

Authors:  Z Mor; N Nuss; M Savion; I Nissan; M Lidji; S Maneshcu; H Kaidar-Shwartz; Z Amitai; E Rorman; R Sheffer
Journal:  Isr J Health Policy Res       Date:  2018-07-15

8.  Factors influencing active tuberculosis case-finding policy development and implementation: a scoping review.

Authors:  Olivia Biermann; Knut Lönnroth; Maxine Caws; Kerri Viney
Journal:  BMJ Open       Date:  2019-12-11       Impact factor: 2.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.